Dutasteride
NDC Package 51013-190-30

11-digit billing NDC: 51013019030

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Dutasteride is capsules are contraindicated for use in:•Pregnancy. Marketed by Puracap Pharmaceutical Llc, this product is identified by NDC 51013-190 and is authorized under FDA application ANDA209909.

Identification & Billing

NDC Package Code
51013-190-30
Package Description
30 CAPSULE, LIQUID FILLED in 1 BOTTLE
Product Code
11-Digit Billing Format
51013019030
RxNorm Crosswalk
RxCUI: 351172 - dutasteride 0.5 MG Oral Capsule

Clinical Specifications

Proprietary Name
Dutasteride
Dosage Form
-
Usage Information
Dutasteride capsules are contraindicated for use in:•Pregnancy. In animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. Therefore, dutasteride may cause fetal harm when administered to a pregnant woman. If dutasteride is used during pregnancy or if the patient becomes pregnant while taking dutasteride, the patient should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)].•Women of childbearing potential [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)].•Pediatric patients [see Use in Specific Populations (8.4)].•Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2)].

Regulatory & Marketing

Labeler Name
Puracap Pharmaceutical Llc
FDA Application #
ANDA209909
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-29-2018
Listing Expiration
12-31-2024
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (51013-190). Click a package code to view its specific billing and regulatory data.

90 CAPSULE, LIQUID FILLED in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51013-190-30 identifies a specific commercial package of 30 capsule, liquid filled in 1 bottle of Dutasteride, labeled by Puracap Pharmaceutical Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Puracap Pharmaceutical Llc on May 29, 2018. The current certification is valid through December 31, 2024.

How is this Puracap Pharmaceutical Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51013019030. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
51013-190-30
11-Digit CMS (5-4-2)
51013-0190-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.